Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Protagonist Therapeutics Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners. These examiners are located within 2 distinct art units, indicating a degree of technical concentration in the company's current patenting efforts.
The busiest examiner, COFFA, SERGIO, is responsible for 1 pending office action. With 3 pending office actions and 3 distinct examiners, the workload is evenly split, with each examiner handling 1 action. The presence of 2 distinct art units for 3 examiners suggests that the underlying technology is being reviewed by multiple individuals within a limited number of specialized USPTO groups.
This requires the applicant to manage 3 different examiner styles while adhering to the specific guidelines of 2 distinct art units. The fact that 3 distinct examiners are involved means that the prosecution strategy must be personalized for each action. However, the use of 2 distinct art units provides a more stable regulatory environment than a portfolio spread across more numerous units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
| HA, JULIE | 1 | 75.7% | +44.0% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18492612 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | COFFA, SERGIO | — |
| 18016825 | Conjugated Hepcidin Mimetics | HA, JULIE | — |
| 17792594 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18492612 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | COFFA, SERGIO | 1658 | §112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18016825 | Conjugated Hepcidin Mimetics | HA, JULIE | 1654 | DP | Non-Final OA | — | Pending | Jan 18, 2023 |
| 17792594 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | DABKOWSKI, ERINNE R | 1658 | §103§112DP | Non-Final OA | — | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial